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Background: TGFβ-induced (TGFBI/βig-H3) is a protein inducible by TGFβ1 and secreted by many types of cells. It
binds to collagen, forms part of the extracellular matrix (ECM), and interacts with integrins on cell surfaces. In this
study, we investigated the role of TGFBI in tumorigenesis and the underlying mechanisms.
Methods: Patient serum TGFBI levels were determined by ELISA. TGFBI transgenic and gene knockout mice and
TGFBI-overexpressing liver cells were used for mechanistic studies.
Results: We demonstrated that patients with cholangiocarcinomas, hepatic carcinomas or gastric carcinomas
presented significantly elevated serum TGFBI levels, and the excess TGFBI was derived from the tumor masses.
TGFBI overexpression in mice resulted in increased incidence of spontaneous tumors and N,N-diethylnitrosamine
(DEN)-induced liver tumor nodules, compared to that in wild type (WT) mice, while TGFBI knockout mice were
comparable to WT controls in these 2 aspects. TGFBI promoted the survival of Aml-12 liver cells with DNA damage
after irradiation, and augmented their post-irradiation proliferation. It activated the FAK/AKT/AKT1S1/PRS6/EIF4EBP
pathway, which is known to modulate cell survival and proliferation.
Conclusions: Our data suggest that TGFBI functions as a promoter of certain gastrointestinal tract cancers. It
provides a survival advantage to cells with DNA damage. Over a long time span, this advantage could translate
into increased tumor risks.
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Patient serum TGFBI levelsBackground
TGFBI, also known as βig-H3, is a gene cloned from
TGFβ1-stimulated A549 lung adenocarcinoma cells [1].
TGFBI protein has an N-terminal secretory signal (amino
acids 1–23), 4 FAS1 homologous internal domains, and a
cell attachment RGD domain at its C-terminus [2]. It is pro-
duced by many cell types [3,4].
Quite a few correlative studies have revealed conflicting
roles of TGFBI as either tumor suppressor or promoter.
TGFBI down-regulation has been noted in various tu-
mors. For example, TGFBI loss or down-regulation has
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unless otherwise stated.immunohistochemistry [5,6]. TGFBI mRNA is down-
regulated in human and mouse mixed lineage leukemia
[7]. TGFBI promoter hypermethylation, which sup-
presses TGFΒΙ expression, is found in ovarian carcin-
oma specimens [8]. TGFΒΙ promoter hypermethylation
is also correlated with the metastatic phenotype of lung,
prostate and ovarian carcinomas [8-11]. Lung carcin-
omas overexpressing TGFΒΙ show increased sensitivity
to chemotherapy [12]. Decreased TGFΒΙ expression in
ovarian carcinomas elicits Paclitaxel resistance [13].
TGFBI protein expression is reduced in breast carcin-
oma cells [14]. These findings suggest that TGFBI func-
tions as a tumor suppressor.
On the other hand, TGFBI upregulation has also been
reported to be associated with tumorigenesis. Immunohis-
tochemistry has determined that human colon carcinomas
manifest increased TGFBI expression [15]. Based on
microarray analysis, TGFBI is among a number of genesis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain





















Figure 1 Elevated serum TGFBI levels in patients with 3 types
of gastrointestinal tract carcinomas. Each patient serum sample
was measured in duplicate for TGFBI levels with ELISA, and the
mean of each sample was plotted as a dot, with tumor type and
patient number indicated; the horizontal bars are group medians.
TGFBI levels in patients of each tumor type were compared with
those in control patients. Statistical significance is indicated by
asterisks. **p < 0.01 (2-tailed Student’s t test).
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man squamous cell carcinomas [17]. mRNA expression and
immunohistochemistry studies have revealed that TGFBI is
one of the genes overexpressed abnormally in colon carcin-
omas and adenomas [18]. In silico analysis of a protein-
protein interaction database has disclosed enhanced TGFBI
expression by esophageal squamous cell carcinomas
[19]. These findings suggests that TGFBI functions as a
tumor promoter.
There are more causative evidences pointing to either the
negative or positive involvement of TGFBI in tumorigenesis.
TGFBI is reported to have tumor suppressor-like func-
tions. For example, TGFBI overexpression inhibits tumori-
genesis and reduces the mobility of lung carcinoma cells
[14,20]. TGFBI hampers neuroblastoma cell proliferation
and invasion [21,22]. The C-terminal fragment of TGFBI
induces human osteosarcoma and lung carcinoma cell
apoptosis [23,24]. TGFBI knockdown promotes the prolif-
eration of mesothelioma cells [25]. TGFBI evokes apop-
tosis of ovarian carcinoma cells [11]. Aged TGFBI gene
knockout (KO) mice manifest increased tumor risks (37%
versus 8.3% in wild type (WT)) mice at 13–20.5 months of
age [26]. These KO mice also have a higher incidence of
chemically-induced skin cancer (40% versus 5% in WT
controls at 6 months after induction). Lung carcinoma
cells transfected with a TGFBI-expressing construct fail to
establish tumors in mice in vivo whereas empty vector-
transfected cells do, indicating a suppressive effect of
TGFBI on tumor formation [5].
However, multiple studies report a causative tumor-
promoting function of TGFBI. TGFBI overexpression in
colon carcinoma cells enhances their metastasis in mice
in vivo [15]. Recombinant TGFBI promotes ovarian carcin-
oma cell mobility and invasiveness [11]. TGFBI interacts
with integrin to promote hepatocellular carcinoma cell in-
vasiveness, while TGFBI knockdown reduces it [27,28].
TGFBI knockdown also attenuates glioma cell invasiveness
[29]. Recombinant TGFBI induces lung carcinoma A549
cell growth. Of course, invasiveness and mobility are not
tumorigenesis, but both favor secondary tumor formation.
We conducted human and animal studies to assess the
role of TGFBI in tumorigenesis in an attempt to better
understand the reasons underlying conflicting observa-
tions on the pro- and anti-tumor effects of TGFBI.
Results
Elevated serum TGFBI levels in certain gastrointestinal
tract cancer patients
We assessed serum TGFBI levels in 427 patients admitted
to surgical wards of the Second Affiliated Hospital of
Zhejiang University and diagnosed with various malignant
tumors: cholangiocarcinomas (n = 22), pancreatic carcin-
omas (n = 68), hepatic carcinomas (n = 47), lung carcin-
omas (n = 80), gastric carcinomas (n = 36), mammarycarcinomas (n = 32), colon carcinomas (n = 62), brain car-
cinomas (n = 16), malignant lymphomas (n = 13), esopha-
geal carcinomas (n = 15), prostate carcinomas (n = 10),
and osteosarcomas (n = 26). Two hundred and sixteen
surgical patients, admitted to the same surgery wards
during the same time period as were the malignant tumor
patients but with non-tumor conditions, were considered
as controls. Identical blood collection and sample preser-
vation procedures were employed for the 2 cohorts.
Serum TGFBI levels non-malignant tumor patients and
controls are reported in Figure 1 as scatter plots with hori-
zontal bars indicating medians, to show their distribution
in each tumor type. Compared to the non-tumor controls,
cholangiocarcinoma, hepatocellular carcinoma, and gas-
tric carcinoma patients presented significantly elevated
serum TGFBI levels, with cholangiocarcinoma cases hav-
ing the highest values. We pooled the data on all non-
tumor patients and stratified them by age and gender, but
neither of these 2 variables seemed to influence serum
TGFBI levels (data not shown), suggesting that under the
non-tumor condition, the age and gender do not influence
the serum TGFBI levels. We also analysed TGFBI levels in
cholagiocarcinoma, hepatocarcinoma, gastric carcinoma
and pancreatic carcinoma patients for their association
with clinical tumor stages, but no significant association
was observed (data not shown).
We tested serum TGFBI levels of some tumor patients
before and after treatment (tumorectomy, chemotherapy
Han et al. Molecular Cancer  (2015) 14:64 Page 3 of 12or irradiation). Because of logistic difficulties, the majority of
patients tested before and after treatment were not the same
ones. Serum TGFBI levels in patients before and after treat-
ment are illustrated in scatter plots in Figure 2A. They were
significantly lower in cholangiocarcinoma, hepatocellular
carcinoma and gastric carcinoma patients after the treat-
ment than before the treatment. Individual treatment sub-
group (i.e., tumorectomy, chemotherapy or irradiation) did
not present significant difference compared to the group
without treatments, probably due to insufficient sample
sizes. We managed to obtain sera from 7 tumor patients be-
fore and after the treatments as a self-controlled sub-cohort.

































































Figure 2 Serum TGFBI levels in carcinoma patients before and after t
treatment. Serum TGFBI levels were measured in a cohort of patients with
different cohort with the same 4 types of cancers were quantified after tre
are scatter- plotted in A, with each dot or triangle representing mean serum
The numbers of patients in each category and carcinoma type are indicate
**: Statistically significant differences (p < 0.01) between pre- and post-treat
in a self-controlled cohort of carcinoma patients. Serum TGFBI levels of 7 car
carcinomas, and 3 with pancreatic carcinomas) were measured before and
plotted. Levels after treatment were significantly lower than before treatme
in certain gastrointestinal tract carcinomas according to immunohistochemist
hepatocarcinoma and gastric carcinoma (left column) were stained with an
higher magnification show intracellular TGFBI staining. Normal tissues fromtreatment (Figure 2B). We assessed tumor sections from
cholangiocarcinomas, pancreatic carcinomas, hepatocarci-
nomas and gastric carcinomas for TGFBI expression with
immunohistochemistry. As shown in Figure 2C (left col-
umn), these tumor sections were rich in TGFBI signals, both
intracellularly (see insets of higher magnification) and in
ECM. The detection of TGFBI in ECM is expected as it
binds to collagens after being secreted from the source cells.
On the other hand, no obvious TGFBI signal was detectable
in normal bile duct, pancreas live and stomach tissues
(Figure 2C, right column).
Collectively, these data indicate that serum TGFBI
















reatment. (A) Reduced serum TGFBI levels in carcinoma patients after
4 types of gastrointestinal tract carcinomas. Serum TGFBI levels from a
atments (i.e., tumorectomy, chemotherapy, or irradiation). The results
TGFBI titre of a patient. The horizontal bars denote group medians.
d. Serum TGFBI levels in non-tumor patients were included as controls.
ment cohorts (2-tailed Student’s t test). (B) Reduced serum TGFBI levels
cinoma patients (1 with cholangiocarcinoma, 3 with hepatocellular
after treatments (tumorectomy, chemotherapy and irradiation) and
nt (**: p < 0.01; 2-tailed Student’s t test). (C) Elevated TGFBI expression
ry. Cryosections of human holagiocarcinoma, pancreatic carcinoma,
ti-TGFBI Ab and TGFBI signals are revealed in brown. Insets with
these human organs were used as controls (right column).
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TGFBI in the blood. Further, the serum TGFBI levels are
influenced by tumor treatment.
TGFBI overexpression but not TGFBI KO increases
spontaneous tumor incidence in aged mice
The clinical data demonstrated elevated serum TGFBI
levels in patients with certain types of tumors. We won-
dered whether increased TGFBI levels caused tumorigen-
esis. To address this question, we assessed spontaneous
tumor incidence in aged (>16-month-old) Tg mice with β-
actin promoter-driven over-expression of TGFBI. Various
organs of the Tg mice clearly overexpressed TGFBI, as this
transgene was driven by an actin promoter (Figure 3A).
Mice were sacrificed and/or autopsied starting from age
16 months if one of the following conditions was met: 1)
palpable lumps in abdomen; 2) loss of more than 20%
body weight; 3) death from unknown causes; 4) reached
age 22 months. Spontaneous tumors were found in 10 out
of 28 Tg mice (35.7%), but none was found in 21 WTcon-
trols (Figure 3B). At autopsy, these mice presented visceral
tumor masses measuring 2 to 30 mm in greatest diameter
(Figure 3C). Histologically, the tumor nodules or masses
ranged from preneoplastic nodular hyperplasia to frank
hepatocellular carcinomas in the liver (Figure 3D, upper
panel), gastric intramucosal adenocarcinomas arising in
adenomas (Figure 3D, middle panel), and malignant neo-
plasms histologically consistent with malignant lymph-
omas in the spleen (Figure 3D, lower panel, and data not
shown). However, no WT littermates died or developed
abdominal tumor masses during the same period. The dif-
ference was highly significant, indicating that TGFBI over-
expression was tumorigenic.
Among KO mice, only 1 out of 17 (5.8%) developed visible
tumor masses spontaneously between 16 and 22 months of
age (Figure 3E), and was not statistically significantly differ-
ent fromWT littermates (1 out of 14; 7.1%).
TGFBI overexpression but not TGFBI KO increases liver
tumor incidence in mice fed DEN
To corroborate observations based on spontaneous tumor
incidence in aged mice, we tested the effect of TGFBI
overexpression and KO in mice exposed to DEN. After 3-
month DEN treatment, whitish tumor nodules of various
sizes (normally less than 3 mm in diameter) developed on
the liver surfaces of some mice. Seven out of 9 (77.8%) Tg
mice but only 2 out 8 (25%) WT littermates developed
tumor nodules in their livers (Figure 4A; left panel). The
difference was statistically significant. Also, Tg mice pre-
sented significantly larger numbers of tumor nodules per
liver than WTcontrols (Figure 4B).
Histologically, typical tumor nodules from Tg livers after
3 months of DEN treatment gave the impression of pre-
neoplastic hepatic nodular hyperplasia (Figure 4C-a andC-b, solid arrows), along with chronic inflammation and
bile ductule proliferation, most severe in portal and peri-
portal areas (Figure 4C-b, empty arrows). In some Tg
mice, proliferating bile ductules formed anastomosing and
distorted tubules with epithelial dysplasia (data not
shown). The degree of abnormal bile ductule proliferation
and associated inflammation after DEN treatment was
most severe in Tg mice and least severe in WT. While KO
mice also demonstrated increased chronic inflammation
and bile ductule proliferation compared to WT controls,
their degree was less severe than that of Tg mice (data not
shown). Proliferating cell nuclear antigen (PCNA) staining
revealed that the nodules from Tg livers contained numer-
ous actively-proliferating hepatocytes, while such nests
were much fewer and smaller in WT and KO livers
(Figure 4C-c, d, and e).
At 5 months of DEN treatment, most Tg (91.7%) and
WT (75%) mice developed tumor nodules, and the differ-
ence was not statistically significant (Figure 4B, right panel),
nor was the difference in numbers of tumor nodules per
liver (data not shown).
In TGFBI KO mice and their WT littermates, DEN treat-
ment caused no significant differences in tumor incidence
after either 3 or 5 months, although, as expected, 5-month
treatment induced greater tumor incidence than 3-month
treatment (Figure 4D).
TGFBI reduces liver cell apoptosis after DNA damage and
promotes cell proliferation after irradiation
Aml-12 cells are mouse hepatocytes that are non-
transformed but immortal due to transgenic human TGF
expression. We stably transfected this cell line with a
mouse TGFBI expression construct pCEP4-TGFBI. TGFBI
overexpression by these cells at the mRNA level was proven
by reverse transcription-quantitative polymerase chain
reaction (RT-qPCR) (Figure 5A, left panel), and TGFBI
protein overexpression was demonstrated by enzyme-linked
immunosorbent assay (ELISA) of culture supernatants
(Figure 5A, right panel).
Twenty h after 20-Gy irradiation, vector-transfected
controls and TGFBI-overexpressing Aml-12 cells mani-
fested similar levels of DNA damage according to
H2AX staining (Figure 5B, upper left panel). We gated
H2AX-positive cells and assessed their apoptosis by
caspase-3 staining. As illustrated in the lower left panel
of Figure 5B, TGFBI-expressing, H2AX-positive cells
presented much less apoptosis (10.1%) than vector-
transfected H2AX-positive cells (32.6%). Data from 3
independent experiments are summarized in Figure 5B
(right panel). H2AX-positive, TGFBI-overexpressing
Aml-12 liver cells manifested significantly lower apop-
tosis than their vector-transfected controls.
We next examined TGFBI-overexpressing Aml-12 cell
proliferation after irradiation. Aml-12 cells readily form















































Figure 3 (See legend on next page.)
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Figure 3 Increased tumor incidence in aged TGFBI Tg but not TGFBI KO mice. (A) TGFBI overexpression in TGFBI Tg mice by immunohistochemistry.
Organs from WT and Tg mice were cryosectioned and stained with anti-TGFBI Ab and signals were revealed by Anti-mouse/rabbit Universal
Immunohistochemistry Detection Kit (Proteintech Group). (B) Tumor incidence in aged TGFBI Tg mice. Tg and WT mice were kept under specific
pathogen-free conditions. They were sacrificed and autopsied starting from age 16 months if one of the following conditions was met: 1) palpable
lumps in abdomen; 2) loss of more than 20% body weight; 3) death from unknown causes; 4) reached age 22 months. Percentages of mice with
tumor masses upon visual inspection are reported. The data were analyzed by 2-tailed Student’s t tests. P-value is indicated. (C) Tumor masses in aged
TGFBI Tg mice. Arrows indicate tumor masses in 2 aged TGFBI Tg mice. (D) Histology of tumors in aged TGFBI Tg mice. Upper panel: hepatocellular
carcinoma; middle panel: gastric adenoma, arrows indicate tumorous cells; lower panel: lymphoma-like tumor. (E) Tumor incidence in aged TGFBI KO
mice. Tumor incidence in aged TGFBI KO and WT mice was determined as described in A. The data were analyzed by 2-tailed Student’s t test. P-value
is indicated.
Han et al. Molecular Cancer  (2015) 14:64 Page 6 of 12aggregates that are difficult to disperse. Consequently, it
is technically challenging to precisely enumerate cell num-
ber and culture equal numbers of TGFBI-overexpressing
and vector-transfected control cells. We, therefore, distrib-
uted the same type of cells in duplicate plates, one under-
gone irradiation, and the other cultured without irradiation.
Cell proliferation was assessed by 3H-thymidine uptake,
and uptake ratios between irradiated versus non-irradiated

















































Figure 4 TGFBI Tg but not TGFBI KO mice present increased incidenc
Tg and WT mice with liver tumor nodules after DEN treatment. TGFBI Tg mice
3 months (3 m) or 5 months (5 m) and then sacrificed. Percentages of mic
shown, and mouse number (n) per group indicated. P-values of Tg versus
tumor nodules on liver surface in Tg and WT mice treated with DEN. TGFBI Tg
water for 3 months. Visible tumor nodules on the liver surface were counte
per group shown. The asterisk indicates significant statistical differences (p
mice treated with DEN in drinking water. Arrows indicate multiple whitish tu
for 3 months (a). The liver was stained with hematoxylin-eosin; solid arrows
cell infiltration around blood vessels (b). Representative liver sections from
drinking water for 3 months, were stained with anti-PCNA Ab. Signals appe
nodules after DEN treatment. TGFBI KO mice and their WT littermates were
(5 m), and the percentages of mice with liver tumor nodules are shown.impact of irradiation on proliferation, independent of pre-
cise cell counting. As illustrated in Figure 5C (left panel), ir-
radiation inhibited the proliferation of control Aml-12 cells
more strongly than that of TGFBI-overexpressing cells. The
proliferation index of TGFBI-overexpressing cells in 3 inde-
pendent experiments was significantly higher than that of
control cells (Figure 5C, right panel), indicating that Aml-
























e of carcinogen-induced liver pre-neoplasia. (A) Percentage of TGFBI
and their WT littermates were treated with DEN in drinking water for
e with and without liver tumor nodules upon visual inspection are
WT groups are presented (2-tailed Student’s t test). (B) Number of
mice and their WT littermates were treated with DEN in drinking
d, means ± SD of nodules per liver reported, and mouse number (n)
< 0.05, 2-tailed Student’s t test). (C) Pre-neoplastic liver tumor nodules in
mor nodules on the liver surface from Tg mice on DEN-water drinking
indicate pre-neoplastic hepatocyte nodules; empty arrows point to
TGFBI Tg (c), WT (d) and TGFBI KO (e) mice, treated with DEN in
ar in brown. (D) Percentages of TGFBI KO and WT mice with liver tumor








































































































































Figure 5 TGFBI promotes liver cell survival and proliferation after irradiation. (A) Aml-12 liver cells overexpressed TGFBI after stable transfection
with the TGFBI-expressing construct pCEP4-TGFBI. TGFBI mRNA levels of transfected Aml-12 liver cells were measured by RT-qPCR. β-actin mRNA levels
served as internal controls, and data are expressed as ratios of TGFBI versus β-actin signals (left panel). The supernatants of these cells were quantified
by ELISA in duplicate for TGFBI protein levels; regular culture medium was included as an additional control (right panel). Means ± SD of representative
experiments are shown. (B) TGFBI promotes post-irradiation survival of liver cells carrying DNA damage. TGFBI-overexpressing Aml-12 and control cells
were irradiated at 20 Gy and cultured for 20 h. They were then stained with Abs against γH2AX and caspase-3, and analyzed by flow cytometry. The
percentages of caspase-3-positive cells among γH2AX-positive cells are presented (left), and the percentages of 3 independent experiments are
summarized in the bar graph (right), with p-value indicated (2-tailed Student’s t test). (C) TGFBI promotes post-irradiation proliferation of liver cells.
TGFBI-overexpressing Aml-12 and control cells after irradiation were cultured in complete DMEM/F12 medium containing 10% FCS for 40 h.
3H-thymidine was added 16 h before the cells were harvested. Thymidine uptake of both irradiated and non-irradiated cells in a representative
experiment is shown on the left. Post-irradiation proliferation indices of 3 independent experiments are summarized in a bar graph on the right with
p-value indicated (2-tailed Student’s t test).
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TGFBI is known to bind integrins. In a previous study, we
demonstrated that FAK, which is positioned upstream inthe integrin signaling pathway, is activated in islets upon
TGFBI stimulation [30]. We investigated TGFBI Tg islets
by interrogating Full Moon BioSystem phospho-protein
Han et al. Molecular Cancer  (2015) 14:64 Page 8 of 12arrays containing Abs against 402 phosphorylated kinases,
adaptor proteins, and transcription factors, looking for add-
itional molecules involved in the TGFBI signaling pathway.
A molecule known as AKT1S1 was confirmed to undergo
increased phosphorylation [31]. AKT1S1 is a substrate of
AKT, which is downstream of FAK, and it is also a compo-
nent of the mTOR signaling pathway, which is critical in cell
survival and proliferation [32]. We investigated whether this
molecule and the signaling pathway it is associated with
were also operative in liver cells. Immunoblotting demon-
strated that AKT1S1 phosphorylation (Thr246) was signifi-
cantly increased in TGFBI-overexpressing Aml-12 cells
compared to vector-transfected control cells (Figure 6). Such
up-regulation was accompanied by higher FAK(Tyr397) and
AKT(S473) phosphorylation (Figure 6), reflecting enhanced
upstream signaling strength responsible for AKT1S1
phosphorylation.
AKT1S1 phosphorylation allows it to dissociate from
mTOR complex 1 (mTORC1) and renders mTOR active
[33,34]. Indeed, we determined that 2 downstream mTOR




































































Figure 6 TGFBI increases FAK, AKT AKT1S1, RPS6, and EIF4EBP1 phos
TGFBI-expressing vector (TGFBI-overexpressing) and empty vector (vector-t
EIF4EBP1 phosphorylation according to immunoblotting. Results of represe
versus total proteins in 3 independent experiments are summarized in B. w
(p < 0.05, 2-tailed Student’s t test).Thr46), underwent increased phosphorylation in TGFBI-
overexpressing Aml-12 cells (Figure 6), indicating mTOR
signaling pathway activation due to TGFBI-triggered
signaling.
Discussion
Clinical and mechanistic results argue for TGFBI as both
tumor suppressor and promoter. Convincing evidence sup-
ports both contentions [5-9,11-20,23-29]. Ween et al. [35]
compiled an updated, comprehensive list of articles describ-
ing TGFBI as suppressor and promoter of different cancer
types. The list gives the general impression that TGFBI is a
promoter of gastrointestinal tract cancers, and functions as
a tumor suppressor of other cancers. This impression is
loosely corroborated by our data in that patients with 3
types of gastrointestinal tract carcinomas presented signifi-
cantly higher serum TGFBI levels with excess TGFBI
derived from the tumor masses, whereas they were not ele-
vated in patients with malignant tumors of other origins,
such as bone, prostate, breast, and hematopoietic cells



















phorylation in liver cells. Aml-12 liver cells stably transfected with
ransfected) were assessed for their FAK, AKT AKT1S1, RPS6, and
ntative experiments are shown in A. Ratios of phosphorylated proteins
ith means ± SD indicated. Asterisks denote statistical significance
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omas. With that said, some patients with pancreatic carcin-
omas had high serum TGFBI levels, although TGFBI levels
as a group were not significantly higher than in the controls
(Figure 1). This has raised an intriguing possibility that the
pro- and contra-tumor effects of TGFBI are tissue- and
tumor type-dependent events.
Zhang et al. reported that aged TGFBI KO mice (13–
20.5 months old) presented increased risks of spontaneous
tumors: 37% in KO mice versus 8.3% in WT mice [26].
However, the TGFBI KO mice generated by us had no such
phenotype. As depicted in Figure 3D, the incidence of
spontaneous tumors in our aged KO and WT mice (16–22
months old) was 5.8% and 7.1% respectively, similar to that
in WT controls described in Zhang’s study. In Zhang’s KO
mice, exons 4–6 of the TGFBI gene was deleted, while in
our KO mice, a more extensive deletion from exon 4 to 12
occurred. With that said, both Zhang et al. and we demon-
strated convincingly that TGFBI in these 2 types of KO
mice were deleted. So the degree of gene deletion is un-
likely a reason for the observed discrepancy in the tumor
phenotype. We have noticed that the majority (73.9%; 17 of
23) of tumors in Zhang’s investigation are lymphomas or
due to lymphoproliferative disorder, raising the possibility
that TGFBI KO mice are compromised in certain anti-virus
immune responses, and Zhang’s colony had certain virus
infections, increasing the incidence of lymphomas.
In our experiments, we demonstrated that highTGFBI ex-
pression is associated with 3 types of gastrointestinal carcin-
omas in patients and causes tumorigenesis in mice. We
suspect that the basic mechanism underlying increased
tumor incidence in Tg mice and sub-populations of TGFBI-
overexpressing human cancer patients is that TGFBI pro-
motes the survival of cells which have cancerous gene muta-
tion. To prove our point, we tested whether TGFBI could
promote survival of hepatocytes with DNA damage.
Irradiation-induced DNA damage and DNA-damaged cells
activate checkpoints at different phases of the cell cycle.
Such cell cycle arrest has the benefit of giving cells a time
window for DNA repair. Cells with severe DNA damage
beyond repair will undergo senescence, or apoptosis, with or
without exiting the checkpoints, whereas those with less
damage will exit checkpoints and resume the normal cell
cycle because of: 1) recovery, if the damage is repaired, or 2)
adaptation, in which cycling cells still have DNA damage
[36]. In adapted cells, DNA damage could be detected
by the presence of H2AX [37]. We irradiated TGFBI-
overexpressing Aml-12 liver cells, and found reduced apop-
tosis in H2AX-positive cells, compared to H2AX-positive
control cells which had little TGFBI expression. Also, these
TGFBI-expressing cells after irradiation had a higher prolif-
eration index than control cells. Thus, it is quite possible
that some adapted cells with DNA damage (hence muta-
tions) in the presence of TGFBI have a survival andproliferation advantage over control cells. Of course, not all
H2AX-positive cells will eventually survive in the presence
of TGFBI, but in pathophysiological settings, the survival of
even a tiny fraction of adapted cells over a long period of
time will translate into increased incidence of tumors.
Although TGFBI-overexpressing Aml-12 cells showed
reduced apoptosis after irradiation, the supernatants from
these cells did not seem to protect vector-transfected
Aml-12 cells from irradiation-induced apoptosis (data not
shown). It is possible that the secreted TGFBI is quickly
diluted in the culture medium and cannot reach to a suffi-
ciently high concentration to protect nearby fraternal
cells, while the concentration in the vicinity of the source
cells is high enough to exert the protective autocrine ef-
fects against apoptosis. However, in vivo in tissues packed
with cells, it is still possible for TGFBI from secreting
source cells to protect other cells in the vicinity in a para-
crine way, as there is less dilution under such circum-
stances. It is especially true as the secreted TGFBI will
bind to collagens and accumulate in ECM. Such TGFBI-
enriched ECM will likely provide nearby cells with a sur-
vival advantage.
We discovered that TGFBI augmented AKT1S1 (Thr246)
phosphorylation. AKT1S1 is an AKT substrate that binds
mTORC1 via Raptor and can inhibit mTORC1 autophos-
phorylation as well as its kinase activity [38]. AKT1S1
phosphorylation at Thr246 by AKT elicits its dissociation
from mTORC1 [33], and releases its inhibitory effect on
mTORC1 [34]. AKT1S1 can thus be considered as a
“bridge” between signaling pathways involving AKT and
mTORC1. mTORC1 has 2 kinase substrates. The first is
p70S6K, whose phosphorylation and activation lead to RPS6
phosphorylation. RPS6 is a component of the complex ribo-
some machinery for protein synthesis. It has been proposed
that ribosomes with the highest proportion of phosphory-
lated RPS6 become active and serve as part of polysomes
[39]. EIF4EBP1, the second known mTORC1 substrate, is a
repressor of protein translation [40]. Hypophosphorylated
EIF4EBP1 interacts with EIF4E and prevents recruitment of
the translation machinery to mRNA, thus inhibiting transla-
tion, whereas phosphorylated EIF4EBP1 enhances transla-
tion. The activation of FAK (which is upstream of AKT),
AKT, RPS6 and EIF4EBP1n in liver cells by TGFBI was con-
firmed by Western blotting (Figure 6). Our data suggest that
in liver cells, TGFBI could trigger signaling along the FAK/
AKT/AKT1S1/mTOR pathway which, in turn, is known to
promote cell survival [32] and reduce the death of cells with
DNA damage or mutation, likely favouring tumorigenesis.
Conclusions
In summary, we revealed that patients with cholangiocarci-
nomas, hepatocellular carcinomas or gastric carcinomas
presented elevated serum TGFBI levels. TGFBI-overex-
pressing mice but not TGFBI KO mice showed increased
Han et al. Molecular Cancer  (2015) 14:64 Page 10 of 12incidence of spontaneous tumors and DEN-induced liver
tumor nodules. Mechanistically, TGFBI promoted the sur-
vival and proliferation of liver cells with DNA damage,
and activated the FAK/AKT/AKT1S1/PRS6/EIF4EBP




A cohort of 427 patients with confirmed diagnoses of vari-
ous malignant tumors according to pathology was
recruited to this study in the Department of Surgery,
the Second Affiliated Hospital of Zhejiang University,
Hangzhou, China. Blood was collected before treatment
(tumorectomy, chemotherapy or irradiation) and, in
some cases, after treatment. A cohort of 216 patients,
admitted to the Department of Surgery for diseases
other than malignant tumors, served as controls. These
patients had no previous history of malignant tumors or
symptoms, or laboratory findings indicating the exist-
ence of such tumors at the time of blood collection. In-
formed consent was obtained from patients before the
donation of their blood samples for this study, which
was performed in accordance with institutional ethics
guidelines and was approved by the Second Affiliated
Hospital Ethics Committee of Zhejiang University. Blood
samples were rested at room temperature for 1–2 hours
after being drawn from the patients. The samples were
centrifuged at 1,400 g for 15 min at room temperature, and
sera were collected and stored at −80°C until being assayed
for TGFBI levels with ELISA. The serum TGFBI levels of
patients of different groups tested were assessed by normal
probability plots and were found to be of sufficient normal
distribution for Student’s t tests.
ELISA
Human and mouse TGFBI ELISA kits were purchased
from R&D Systems (Minneapolis, MN). Human sera were
diluted at 1:2000 with PBS for ELISA. Assays were under-
taken as per the manufacturer’s instructions. All samples
were tested in duplicate, and medians or means were com-
puted for data presentation. Sensitivity was 6 pg/ml with
human TGFBI ELISA, and 8 pg/ml with mouse TGFBI
ELISA. Standard curves were constructed for each batch of
ELISA using recombinant TGFBI. Inter-assay coefficient of
variation was less than 5%.
TGFBI transgenic (Tg) and KO mice
Tg mice with actin promoter-driven TGFBI overexpres-
sion and TGFBI KO mice were generated in our labora-
tory, and their TGFBI overexpression and KO at the
mRNA and proteins levels were fully characterized in our
previous publications [30,31]. All mice were housed under
specific pathogen-free conditions and studied accordingto protocols approved by the institutional Animal Protec-
tion Committee of the CRCHUM.Immunohistochemistry
Immunohistochemistry for PCNA is described in our pre-
vious publication [31]. Briefly, paraffin-fixed sections of
liver tissues were stained with mouse anti-PCNA mAb
(Cell Signaling Technology, Danvers, MA; 1:100 dilution).
Horse radish peroxidase-linked sheep anti-mouse IgG Ab
(GE Healthcare, Little Chalfont, Buckinghamshire, UK;
1:200 dilution) served as the secondary Ab. PCNA signals
were assessed by DAB substrate kit (BD Biosciences,
Mississauga, Ontario, Canada). Details are also available in
the standard immunohistochemistry protocol of Cell Sig-
naling Technology.
For TGFBI protein expression in human cancers, normal
tissues and TGFBI Tg and WT organs, frozen sections of
tumors or tissues were stained with rabbit anti-TGFβi mAb
(Proteintech Group, Chicago, IL; 1:50 dilution). TGFβi sig-
nals were revealed by Anti-mouse/rabbit Universal Immu-
nohistochemistry Detection Kit (Proteintech Group). The
sections were then counter-stained with hematoxylin.Induction of liver tumors with N,N-diethylnitrosamine
(DEN)
Four- to 5-week-old male Tg, KO and WT mice in the
C57BL/6 J background were given water containing 10 mg/l
DEN (Sigma, St. Louis, MO) for 3 to 5 months before sacri-
fice. Liver tumor incidence was documented, as were tumor
nodule number and size on liver surfaces.Plasmid construction and stable transfection
Full-length human TGFBI cDNA (MGC-1598; Open Bio-
systems/Thermo Scientific, Ottawa, Ontario, Canada) was
cloned into mammalian cell expression vector pCEP4
(Invitrogen, Carlsbad, CA) between KpnI and NotI sites
downstream of the CMV promoter. The resulting plasmid
was named pCEP4-TGFBI. Mouse Aml-12 liver cells were
transfected with pCEP4-TGFBI (2 μg/ml plasmid for 0.2 ×
105 Aml-12 cells/0.2 ml/well in 48-well plates) using X-
treme GENE transfection reagent (Roche Diagnostics,
Laval, Quebec, Canada) according to the manufacturer’s
instructions. The cells were cultured in complete DMEM/
F12 medium containing 10% fetal calf serum (FCS), 1×
ITS Universal Culture Supplements (BD Biosciences), 1×
MEM non-essential amino acids, 1 mM sodium pyruvate
and 40 μg/l dexamethasone. Starting 48 h after transfec-
tion, 800 μg/ml hygromycin B (Invitrogen/Life Tech-
nologies) was present in the culture media for stable
transfectant selection. TGFBI overexpression by stably
transfected Aml-12 cells was confirmed by RT-qPCR
and ELISA.
Han et al. Molecular Cancer  (2015) 14:64 Page 11 of 12RT-qPCR
Total RNA from Aml-12 liver cells was extracted with TRI-
zol (Invitrogen/Life Technologies). RNA was reverse-
transcribed into cDNA with iScriptcDNA synthesis kits
(Bio-Rad Laboratories, Hercules, CA). iQ SYBR Green
Supermix PCR kits (Bio-Rad Laboratories) were employed
for qPCR amplification of cDNA templates. The 5′ and 3′
primers were 5′-TTCCCTATTGTGACA GAGCCATGGT
G-3′ and 5′-CACTGCATTCTAGTTGTGGTTTGTC C-
3′, respectively. The PCR amplification program was as fol-
lows: 95°C, 3 min, 1 cycle; 95°C, 10 s, 59°C, 20 s, 72°C, 30 s,
45 cycles; with melting curves analyzed around 20–25 cy-
cles. All samples were tested in duplicate. β-actin mRNA
levels were considered as internal controls. In addition to
melting curve analysis, qPCR products were verified by agar-
ose gel electrophoresis for expected band sizes. The data are
expressed as signal ratios of TGFBI mRNA/β-actin mRNA.
Irradiation of Aml-12 cells
Aml-12 liver cells stably transfected with pCEP4-TGFBI
or empty pCEP4 vector were irradiated at 20 Gy, and
cultured in complete DMEM/F12 medium containing
10% FCS at 37°C for 20 h. They were assessed for DNA
damage, apoptosis and proliferation.
Flow cytometry
DNA damage and apoptosis of irradiated pCEP4-
TGFBI- or empty pCEP4 vector-transfected Aml-12
cells were investigated by 2-color flow cytometry. They
were first fixed and permeabilized using the eBioscience
Fixation/Permeabilization Kit (eBioscience, San Diego,
CA), and then stained with PE-conjugated rabbit anti-
mouse phospho-histone H2AX (γH2AX) Ab and Alexa
488-conjugated rabbit anti-mouse cleaved caspase-3 Ab
(Cell Signaling Technology).
Post-irradiation proliferation of Aml-12 cells
Aml-12 cells were aliquoted with equal density into 2 sets
of 96-well plates: one set was irradiated at 20 Gy, while
the other was not. The cells were cultured for 48 h in
complete DMEM/F12 medium containing 10% FCS. 3H-
thymidine was added to culture 16 h before harvesting, as
detailed previously [41]. Post-irradiation cell proliferation
indices were calculated as follows:
Post-irradiation proliferation index = cpm of cells post-
irradiation/cpm of cells without irradiation.
Immunoblotting
Aml-12 liver cells stably transfected with pCEP4-TGFBI or
empty pCEP4 vector were cultured overnight in serum-free
DMEM/F12 medium containing 2% BSA, 1 × ITS Universal
Culture Supplement, 1× MEM non-essential amino acids,
1 mM sodium pyruvate and 40 μg/l dexamethasone), and
then lysed. Fifty μg of lysate proteins per lane were loadedfor 10% SDS-PAGE. Proteins in the gels were transferred to
polyvinylidene fluoride membranes after electrophoresis.
The membranes were hybridized with rabbit Abs against
total or phosphorylated mouse FAK (Tyr397), AKT (S473),
AKT1S1 (Thr246), RPS6 (S235/S236), and EIF4EBP1 (Thr3
7/Thr46). All Abs were from Cell Signaling Technology and
used at 1:1,000 dilution. Hybridization was performed ac-
cording to Cell Signaling Technology instructions. Signals
were detected with SuperSignal West Pico Chemilumines-
cent Substrate (Thermo Scientific).
Data analysis
The data are expressed as means ± SD. Medians are indi-
cated in some figures. Statistical significance (p < 0.05) was
determined by 2-tailed Student’s t tests for data with nor-
mal distribution.
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